# EDGAR Filing Document

**Accession Number:** 0000715446
**File Stem:** 0001493152-25-015776
**Filing Date:** 2025-9
**Character Count:** 1979
**Document Hash:** 1c823ea3234bf9f13420e9e086a2d2c7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-015776.hdr.sgml**: 20260204

**ACCESSION NUMBER**: 0001493152-25-015776

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250926

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Anixa Biosciences Inc
- **CENTRAL INDEX KEY:** 0000715446
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 112622630
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1031

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 3150 ALMADEN EXPRESSWAY, SUITE 250
- **CITY:** SAN JOSE
- **STATE:** CA
- **ZIP:** 95118
- **BUSINESS PHONE:** 408-708-9808

**MAIL ADDRESS:**
- **STREET 1:** 3150 ALMADEN EXPRESSWAY, SUITE 250
- **CITY:** SAN JOSE
- **STATE:** CA
- **ZIP:** 95118

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ITUS Corp
- **DATE OF NAME CHANGE:** 20140902

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** COPYTELE INC
- **DATE OF NAME CHANGE:** 19920703

**Anixa Biosciences, Inc.**

**3150 Almaden Expressway, Suite 250** 

**San Jose, CA 95118**

September 26, 2025

**<u>VIA EDGAR</u>**

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, NE

Washington, D.C. 20549

Attention: Chris Edwards

Re: Anixa Biosciences, Inc. <br> Registration Statement on Form S-3 Filed September 10, 2025 <br> File No. 333-290178

Dear Mr. Edwards:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Anixa Biosciences, Inc. hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 5:00 p.m. ET on Tuesday, September 30, 2025, or as soon as thereafter practicable.

---

| |
|:---|
| Very truly yours, |
| */s/ Dr. Amit Kumar* |
| Dr. Amit Kumar |
| Chairman and Chief Executive Officer |

---

cc: Ellenoff Grossman & Schole LLP